Intercure (INCR) vs OS Therapies (OSTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
OS Therapies (OSTX) has outperformed Intercure (INCR) over the past year, losing 20.6% versus a loss of 37.5%. OS Therapies is the larger company by market cap ($75.8 million vs $75.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INCR | OSTX |
|---|---|---|
| Share price | $5.03 | $1.62 |
| Market cap | $75.47M | $75.82M |
| 1-day change | -1.95% | +4.52% |
| YTD return | +10.55% | +15.71% |
| 1-year return | -37.52% | -20.59% |
| 5-year return | -85.53% | — |
| Forward P/E | — | 4.67 |
| EPS (TTM) | $-0.95 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.45 | $2.25 |
| 52-week low | $3.40 | $1.15 |
| Distance from 52-week high | -40.47% | -28.00% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +424.69% |
| Average volume | 21.69K | 597.09K |
| Shares outstanding | 15.00M | 46.81M |
| Employees | 285 | 4 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OSTX has outperformed INCR by 16.9 percentage points over the past year.
About Intercure
INCR stock →InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.
Healthcare · Drug Manufacturers - Specialty & Generic · 285 employees
About OS Therapies
OSTX stock →OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
Healthcare · Biotechnology · 4 employees
INCR vs OSTX FAQ
Which is bigger, Intercure or OS Therapies?
OS Therapies (OSTX) is larger, with a market capitalization of $75.82M compared with $75.47M for Intercure (INCR).
Which stock has performed better over the past year, INCR or OSTX?
OSTX returned -20.59% over the past 12 months, compared with -37.52% for INCR (price return, excluding dividends). Past performance does not predict future results.
Are Intercure and OS Therapies in the same industry?
Both are in the Healthcare sector, but in different industries: Drug Manufacturers - Specialty & Generic for Intercure and Biotechnology for OS Therapies.